406 related articles for article (PubMed ID: 34301173)
1. Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials.
Tepper SJ; Ashina M; Reuter U; Hallström Y; Broessner G; Bonner JH; Picard H; Cheng S; Chou DE; Zhang F; Klatt J; Mikol DD
J Headache Pain; 2021 Jul; 22(1):81. PubMed ID: 34301173
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy and safety during open-label erenumab treatment in Japanese patients with episodic migraine.
Sakai F; Takeshima T; Tatsuoka Y; Hirata K; Cheng S; Numachi Y; Peng C; Xue F; Mikol DD
Headache; 2021 Apr; 61(4):653-661. PubMed ID: 33764538
[TBL] [Abstract][Full Text] [Related]
3. The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% Response.
Broessner G; Reuter U; Bonner JH; Dodick DW; Hallström Y; Picard H; Zhang F; Lenz RA; Klatt J; Mikol DD
Headache; 2020 Oct; 60(9):2026-2040. PubMed ID: 32851644
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy and safety of erenumab in Japanese patients with episodic and chronic migraine: results from a 28-week open-label treatment period of a randomised trial.
Hirata K; Takeshima T; Sakai F; Numachi Y; Yoshida R; Koukakis R; Hasebe M; Yui D; da Silva Lima GP; Cheng S
BMJ Open; 2023 Aug; 13(8):e068616. PubMed ID: 37597868
[TBL] [Abstract][Full Text] [Related]
5. Reduction in migraine pain intensity in patients treated with erenumab: A post hoc analysis of two pivotal randomized studies.
Lipton RB; Dodick DW; Kudrow D; Reuter U; Tenenbaum N; Zhang F; Lima GPDS; Chou DE; Mikol DD
Cephalalgia; 2021 Dec; 41(14):1458-1466. PubMed ID: 34407654
[TBL] [Abstract][Full Text] [Related]
6. Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE.
Alsaadi T; Noori S; Varakian R; Youssef S; Almadani A
BMC Neurol; 2022 Jun; 22(1):221. PubMed ID: 35710354
[TBL] [Abstract][Full Text] [Related]
7. A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults.
Sakai F; Takeshima T; Tatsuoka Y; Hirata K; Lenz R; Wang Y; Cheng S; Hirama T; Mikol DD
Headache; 2019 Nov; 59(10):1731-1742. PubMed ID: 31612482
[TBL] [Abstract][Full Text] [Related]
8. Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study.
Takeshima T; Sakai F; Hirata K; Imai N; Matsumori Y; Yoshida R; Peng C; Cheng S; Mikol DD
Headache; 2021 Jun; 61(6):927-935. PubMed ID: 34153117
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of erenumab in women with a history of menstrual migraine.
Pavlovic JM; Paemeleire K; Göbel H; Bonner J; Rapoport A; Kagan R; Zhang F; Picard H; Mikol DD
J Headache Pain; 2020 Aug; 21(1):95. PubMed ID: 32746775
[TBL] [Abstract][Full Text] [Related]
10. One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study.
Goadsby PJ; Reuter U; Hallström Y; Broessner G; Bonner JH; Zhang F; Wright IK; Chou DE; Klatt J; Picard H; Lenz RA; Mikol DD
Neurology; 2020 Aug; 95(5):e469-e479. PubMed ID: 32636324
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysis.
Tepper SJ; Lipton RB; Silberstein SD; Kudrow D; Ashina M; Reuter U; Dodick DW; Wang A; Cheng S; Klatt J; Mikol DD
Headache; 2023 Jun; 63(6):730-742. PubMed ID: 37313616
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Erenumab for Migraine Prevention in Japanese Patients with Episodic and Chronic Migraine: Results of a Post-Hoc Pooled Analysis.
Kitamura S; Takeshima T; Yui D; da Silva Lima GP; Koukakis R; Peng C; Yoshida R; Numachi Y; Hasebe M
Neurol Ther; 2023 Dec; 12(6):1993-2006. PubMed ID: 37698837
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis.
Ashina M; Tepper SJ; Brandes JL; Reuter U; Boudreau GP; Weatherall M; Gantenbein AR; Doležil D; Klatt J; Wang A; Karanam AK; Cheng S; Mikol DD
Headache; 2022 May; 62(5):624-633. PubMed ID: 35593783
[TBL] [Abstract][Full Text] [Related]
14. A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study.
Yu S; Kim BK; Wang H; Zhou J; Wan Q; Yu T; Lian Y; Arkuszewski M; Ecochard L; Wen S; Yin F; Li Z; Su W; Wang SJ
J Headache Pain; 2022 Nov; 23(1):146. PubMed ID: 36404301
[TBL] [Abstract][Full Text] [Related]
15. Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study.
Barbanti P; Aurilia C; Cevoli S; Egeo G; Fofi L; Messina R; Salerno A; Torelli P; Albanese M; Carnevale A; Bono F; D'Amico D; Filippi M; Altamura C; Vernieri F;
Headache; 2021 Oct; 61(9):1351-1363. PubMed ID: 34309862
[TBL] [Abstract][Full Text] [Related]
16. The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving ≥50%, ≥75%, and 100% response.
Brandes JL; Diener HC; Dolezil D; Freeman MC; McAllister PJ; Winner P; Klatt J; Cheng S; Zhang F; Wen S; Ritter S; Lenz RA; Mikol DD
Cephalalgia; 2020 Jan; 40(1):28-38. PubMed ID: 31816249
[TBL] [Abstract][Full Text] [Related]
17. Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study.
Wang SJ; Roxas AA; Saravia B; Kim BK; Chowdhury D; Riachi N; Tai MS; Tanprawate S; Ngoc TT; Zhao YJ; Mikol DD; Pandhi S; Wen S; Mondal S; Tenenbaum N; Hours-Zesiger P
Cephalalgia; 2021 Nov; 41(13):1285-1297. PubMed ID: 34171973
[TBL] [Abstract][Full Text] [Related]
18. Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial.
Tepper SJ; Diener HC; Ashina M; Brandes JL; Friedman DI; Reuter U; Cheng S; Nilsen J; Leonardi DK; Lenz RA; Mikol DD
Neurology; 2019 May; 92(20):e2309-e2320. PubMed ID: 30996056
[TBL] [Abstract][Full Text] [Related]
19. Erenumab in highly therapy-refractory migraine patients: First German real-world evidence.
Scheffler A; Messel O; Wurthmann S; Nsaka M; Kleinschnitz C; Glas M; Naegel S; Holle D
J Headache Pain; 2020 Jul; 21(1):84. PubMed ID: 32620151
[TBL] [Abstract][Full Text] [Related]
20. Reduction in the severity and duration of headache following fremanezumab treatment in patients with episodic and chronic migraine.
Ashina M; Cohen JM; Gandhi SK; Du E
Headache; 2021 Jun; 61(6):916-926. PubMed ID: 34115380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
